Because MiT family tRCCs express higher levels of phosphorylated S6, which correlates positively with the activation of the mTOR pathway, than most other RCC subtypes, mTOR inhibitors may be a specific therapeutic drug for MiT family tRCC [32,36]. The gene discussed is MTOR; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.